Lung Clinical Trials

2,546 recruitingLast updated: June 17, 2026

There are 2,546 actively recruiting lung clinical trials across 91 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Lung Trials at a Glance

2,546 actively recruiting trials for lung are listed on ClinicalTrialsFinder across 6 cities in 91 countries. The largest study group is Phase 2 with 763 trials, with the heaviest enrollment activity in Houston, New York, and Shanghai. Lead sponsors running lung studies include AstraZeneca, M.D. Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center.

Treatments under study

About Lung Clinical Trials

Looking for clinical trials for Lung? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 2,546 trials

Recruiting
Phase 3

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Non-small Cell Lung Cancer
AstraZeneca675 enrolled283 locationsNCT06357533
Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 2

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer
AbbVie180 enrolled52 locationsNCT07155174
Recruiting
Phase 3

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Small Cell Lung Carcinoma
AstraZeneca70 enrolled15 locationsNCT06992609
Recruiting
Phase 2

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced/Metastatic Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals300 enrolled10 locationsNCT07154290
Recruiting
Phase 1

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled183 locationsNCT06646276
Recruiting

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

Non-small Cell Lung Cancer
AstraZeneca590 enrolled1 locationNCT07413757
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer

Lung CancerRecurrent Lung Cancer
Alpha Tau Medical LTD.10 enrolled1 locationNCT05632913
Recruiting
Phase 1Phase 2

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals80 enrolled3 locationsNCT07564401
Recruiting
Phase 2

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Lung Non-Small Cell Carcinoma
Alliance for Clinical Trials in Oncology164 enrolled28 locationsNCT07293247
Recruiting
Not Applicable

Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery

Video-assisted Thoracoscopic Surgery (VATS)SegmentectomyWedge Resection+3 more
Beijing Tiantan Hospital100 enrolled1 locationNCT07603921
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

ALK-Positive Lung CancerALK-positive Non-small Cell Lung CancerALK-positive NSCLC
TRIANA Biomedicines, Inc.160 enrolled9 locationsNCT07491497
Recruiting

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
N-Power Medicine130 enrolled8 locationsNCT07028489
Recruiting

An External Control Arm Study in Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
N-Power Medicine650 enrolled8 locationsNCT07174388
Recruiting

Study of the Disease Process of Lymphangioleiomyomatosis

PneumothoraxLymphangioleiomyomatosisLung Disease+1 more
National Heart, Lung, and Blood Institute (NHLBI)2,000 enrolled1 locationNCT00001465
Recruiting
Phase 3

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI)300 enrolled603 locationsNCT04181060
Recruiting
Phase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Ovarian NeoplasmsStomach NeoplasmsLung Neoplasms+5 more
National Cancer Institute (NCI)100 enrolled1 locationNCT06885697
Recruiting

Study of Lung Proteins in Patients With Pneumonia

Pulmonary DiseasePneumoniaLung Disease
National Institutes of Health Clinical Center (CC)750 enrolled1 locationNCT00077909